M acrophage migration-inhibitory factor (MIF) is one of the first cytokines to be identified more than 40 years ago. 1 Today, MIF is known as a structurally unique, pleiotropic inflammatory cytokine with chemokine-like properties, which functions as a potent mediator of several inflammatory conditions. [2] [3] [4] However, the role of MIF in cardiovascular diseases, especially in myocardial infarction (MI), has not yet been definitively clarified.
MIF is upregulated in endothelial cells and smooth muscle cells of atherosclerotic arteries, where it contributes to macrophage accumulation and plaque formation. 5, 6 It seems that MIF acts sequentially by first triggering monocyte arrest through the CXCR axis and then promoting monocyte transmigration through the intermediate production of CCL2. 7, 8 Being predominantly expressed in vulnerable plaques and inducing collagen-degrading matrix metalloproteinases, ischemia. 11 A model of acute MI revealed that both MIF mRNA and MIF protein are constitutively expressed at low levels in myocytes of normal and sham-operated rats but rapidly upregulated by surviving cardiomyocytes in the infarcted versus the noninfarcted regions, thereby increasing macrophage infiltration 1 day after acute MI. 12 Furthermore, it seems that cardiomyocytes can secrete MIF through a protein kinase C-dependent pathway in response to reactive oxygen species and hypoxia in the myocardium. 13, 14 Of note, MIF released by cardiomyocytes in a model of myocardial injury induced by 15 minutes of ischemia followed by reperfusion (I/R) injury exerts cardioprotective effects via the CD74/AMPK/c-jun-N-terminal kinase axes, 15, 16 and the protective effect can be enhanced by S-nitrosylation of MIF.
17 CD74 is the cell-surface form of the major histocompatibility complex class II-associated invariant chain (Ii) and was identified to bind MIF by high-affinity interaction and to mediate MIF-induced extracellular signal-regulated kinase 1/2 phosphorylation and cell proliferation. 18, 19 However, some of the cell types targeted by MIF (eg, neutrophils or the cell lines HEK293 and HeLa) do not express CD74 at the surface, 7 raising the need to further clarify the molecular action and functional receptors of MIF in inflammation. Despite the beneficial role of MIF in cardiomyocytes, it was indeed shown that MIF deficiency protected the heart from prolonged, severe I/R injury by suppressing inflammatory responses. 20 Thus, the exact role of MIF in healing after MI and the receptors involved therein are thus far from being completely understood.
Recent data have provided evidence that MIF is a noncognate ligand of the CXC chemokine receptors CXCR2 and CXCR4, thus extending the range of binding partners for MIF. 7 MIF harbors ELR-and N-loop-like motives typically required for CXCR2 activation 21, 22 and has chemoattractant activity toward monocytes and neutrophils through CXCR2, both crucial mechanisms in inflammatory pathologies such as atherosclerosis. 7 Although MIF can bind to CXCR2 or CD74 individually, binding to a CXCR2/CD74 complex seems to further enhance G-protein-coupled receptor activation and atherogenic functions. 7 In addition, MIF can also bind the CXC chemokine ligand 12 (CXCL12) receptor CXCR4, thereby promoting T-cell and endothelial progenitor cell recruitment, 7, 23 enhancing angiogenesis, 24, 25 and inducing phosphorylation of Akt and mitogen-activated protein kinase p42/44. 26 Notably, CXCR2 has been found to exert opposing effects on myocardial viability during I/R, with the recruitment of damaging inflammatory cells prevailing over direct myocardial protection promoted in resident cells, 27 suggesting that CXCR2 may prominently contribute to mediating the effects of MIF in myocardial I/R injury. To shed light on the precise mechanisms enacted by MIF during the myocardial healing response after MI, we aimed to dissect and elucidate the compartment-specific role of CXCR2 in mediating the effects of endogenous MIF in a mouse model of I/R.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Effect of Anti-MIF Antibody on Heart Parameters 1 Week After I/R −/− mice after irradiation (50%) reduced the number of mice in these groups (4 per group).
One week after I/R, both wt/wt BM and wt/Cxcr2 −/− BM mice treated with anti-MIF antibody showed a significant increase in the size of the infarcted area compared with isotype control, whereas Cxcr2 −/− /wt BM mice displayed no effect with anti-MIF ( Figure 1) . In contrast to a previous report, 27 Cxcr2 deficiency in BM cells itself only slightly, but not significantly, reduced the size of the infarcted area after 1 week. In addition, heart function was evaluated by echocardiography before and after myocardial I/R. Before MI, no significant differences were observed among the groups. One week after I/R, anti-MIF antibody treatment significantly decreased the ejection fraction in wt/wt BM and wt/Cxcr2 −/− BM mice compared with untreated mice (Table 2; Figure 2A ). In contrast, treatment with anti-MIF antibody led to a significant increase in ejection fraction in Cxcr2 −/− /wt BM chimera mice compared with isotype control (Table 2; Figure 2A ). Analysis of cardiac output showed good compensation in all groups (Table 2) . Heart rate and weight did not differ among BM chimeras ( Table 2) .
The analysis of cardiac function by Langendorff perfusion 1 week after myocardial I/R revealed corresponding results. Although treatment with anti-MIF antibody decreased left ventricular developed pressure in wt/wt BM and wt/Cxcr2 −/− BM mice compared with isotype control, it significantly improved and restored the impaired left ventricular developed pressure in 
Cxcr2
−/− /wt BM mice ( Figure 2B ). The maximal (dP/dt max ) and minimal (dP/dt min ) pressure change in left ventricle measurements confirmed these results. Treatment with anti-MIF antibody impaired contraction (dP/dt max , Figure 2C ) and relaxation (dP/dt min , Figure 2D ) in wt/wt BM mice and wt/Cxcr2 −/− BM mice but preserved myocardial function in Cxcr2
These data demonstrate that in the presence of wt cardiomyocytes, blocking MIF aggravates myocardial healing and function, thus highlighting that the protective effect of MIF is mediated by a CXCR2-dependent pathway in resident cardiomyocytes. In contrast, neutralizing MIF in the presence of Cxcr2-deficient cardiomyocytes only blocked the detrimental effects of MIF mediated by CXCR2 on BM-derived cells.
Histological and Immunohistochemical Analysis of Infarcted Area
We next analyzed the recruitment of inflammatory cells, neoangiogenesis, and collagen synthesis in the infarcted area 1 day after myocardial I/R. One day after MI, neutrophil infiltration did not significantly differ between the groups ( Figure 3A ; Figure 3B ; Table 3 ). In wt/Cxcr2 −/− BM mice, monocyte infiltration was substantially impaired and not further attenuated by treatment with anti-MIF antibody ( Figure 3B ; Table 3 ), suggesting that the recruitment of monocytes toward the area of the infarction is strictly dependent on CXRC2 in our model. Using CD14/CCR2 double staining, we could now show that most of the infiltrated monocytes are CCR2-positive inflammatory monocytes. This indicates that MIF promotes the recruitment of inflammatory CCR2+ monocytes into the heart tissue ( Figure 3C ; Table 3 ), which dominate the early phase of healing after infarction and exhibit phagocytic, proteolytic, and inflammatory features. 28 Of note, it has already been shown that MIF can recruit inflammatory monocytes in a CCL2-dependent manner, 29 indicating a functional interaction between CXC and CC receptors in the myocardial recruitment of inflammatory monocytes.
Analysis of neoangiogenesis in the infarcted area revealed no significant differences in the level of CD31-positive capillaries between the groups 1 week after MI ( Figure 4A ; Table 3 ), indicating that it was independent of CXCR2 and MIF. Similarly, Langendorff measurements failed to reveal changes in coronary flow in any of the groups ( Figure 4B) .
Notably, collagen content was reduced in all 3 groups by treatment with anti-MIF antibody but not altered by Cxcr2 deficiency in BM or resident cells, demonstrating that collagen deposition 1 week after myocardial I/R was regulated by MIF but not by Cxcr2 ( Figure 5A ; Table 3 ). The number of myofibroblasts did not differ between the groups ( Figure 5B ; Table 3 ), implying that MIF rather affects their function in collagen synthesis. Hence, protective effects of MIF are, in part, attributable to increased collagen deposition, whereas its deleterious effects are as a result of stimulation of myocardial monocyte infiltration.
Discussion
Our data establish a double-edged role of endogenous MIF in the myocardial healing response after I/R injury. To analyze the MIF-CXCR2 pathway, chimeric mice were obtained by reconstitution of wt mice with wt or Cxcr2 −/− BM and of Cxcr2 −/− mice with wt BM. We demonstrate that MIF exerts opposing effects on resident cardiac cells versus BM-derived inflammatory cells mediated through CXCR2. Although blocking endogenous MIF acting through Cxcr2 on cardiomyocytes impaired heart function and increased infarction size, blocking endogenous MIF acting through CXCR2 on circulating inflammatory cells protected heart function and decreased −/− BM mice treated with anti-MIF antibody showed a significant increase in the size of the infarcted area compared with isotype control, whereas the Cxcr2 −/− /wt BM mice displayed no effect after anti-MIF treatment (*P<0.05; n=4-6). infarction size Notably, the latter effect was not related to an infiltration with neutrophils, which did not require Cxcr2 or MIF, but was because of the control of monocyte infiltration in the infarcted area mediated by MIF and CXCR2. Because we did not observe significant differences between the infarction size in isotype-treated wt/wt BM and Cxcr2
−/− /wt BM, it is conceivable that Cxcr2 −/− mice harbor compensatory mechanisms, which may substitute for CXCR2 functions (eg, the CXCR4/CXCL12 axis, CCL2, tumor necrosis factor α, or hypoxia-inducible factor). 30 The oxidoreductive function of MIF has been elegantly shown to provide an antioxidative and cardioprotective capacity in MI 31 and could, therefore, be another compensatory MIF-based protective mechanism in myocardial ischemia/reperfusion injury.
It has previously been shown that MIF released by cardiomyocytes during I/R injury exerts cardioprotective effects by activating AMPK/c-jun-N-terminal kinase through CD74. 15 We observed a reduction in the functional parameters of the heart (ejection fraction, LVED, contraction, and relaxation) and increased infarction size after anti-MIF antibody treatment in wt/wt BM and wt/Cxcr2 −/− BM mice. MIF blockade improved ejection fraction, left ventricular developed pressure, contraction, and relaxation without influencing infarction size in Cxcr2 −/− /wt BM mice, which do not express CXCR2 on cardiomyocytes and, therefore, show impaired heart function after I/R injury compared with controls. It thus seems that protective effects of endogenous MIF secreted by cardiomyocytes can prevent severe functional loss in heart tissue in wt/Cxcr2 −/− BM mice with Cxcr2-deficient circulating cells. Considering what is known about the CD74/AMPK-mediated MIF protection, 15 these results are surprising. Hence, we can assume that CD74 and CXCR2 are both required for myocardial protection in ischemia injury. Although MIF is able to exert its biological effects by binding to CD74 and CXCR2 individually, it was shown that MIF binding to the CXCR2/ CD74 complex enhances G-protein-coupled receptor activation and downstream cardiovascular effects. 7 Accordingly, predictably the deletion of 1 or both of the receptors would attenuate the protective effect in cardiomyocytes exposed to ischemia. Therefore, we suppose that the deletion of both receptors similar to that of Cxcr2 alone would decrease the protective effect of MIF. However, because Cxcr2/Cd74-double deficient mice are not available, we currently cannot verify this notion and thus cannot exclude the compensation of this effect by other MIF-independent protective mechanisms in cardiomyocytes. Nevertheless, the CXCR2/CD74 complex should play a crucial role in mediating the protective effects of MIF in cardiomyocytes after MI.
Notably, deficiency of Cxcr2 in cardiomyocytes and BM-derived inflammatory cells caused only moderate alterations in the size of the infarcted area 1 week after I/R, which contrasts previous findings in BM chimeras after 1 day, as reported by Tarzami et al. 27 Because 1 day after MI the infarction size is largely defined by cardiomyocyte death, this discrepancy may be explained by adaptive remodeling of the infarction area after the inflammatory reaction during the course of 1 week after I/R injury.
In general, MIF blockade reduced the number of inflammatory cells, namely monocytes, infiltrating the site of injury. Mononuclear cells infiltrating the site of inflammation release cytokines and chemokines, which further enhances the recruitment and activation of these proinflammatory cells. 8, 32 It has been shown that MIF can induce monocyte arrest through CXCR2, 7 and accordingly myocardial monocyte infiltration was also dependent on CXCR2 in our study. Studies in animal models characterized by impaired monocyte infiltration have consistently shown preserved heart function after experimental induction of MI. [33] [34] [35] Because we performed our analysis 1 day after I/R, most of the recruited monocytes should be Gr-1 high (also known as Gr-1
) monocytes that dominate the early phase and exhibit phagocytic, proteolytic, and inflammatory features. 28 Reducing inflammatory monocytes after MI seems to beneficially promote cardiac remodeling. 30 Because CXCR2 is absent in inflammatory cells in wt/Cxcr2 −/− BM mice and because the number of infiltrating monocytes was not further reduced by MIF blockade in these mice, we can assume that MIF is able to control the recruitment of inflammatory monocytes. Indeed, MIF has been shown to recruit monocyte/macrophage in a CCL2-dependent manner, because Ccl2 deficiency or anti-CCL2 antibody treatment significantly inhibited MIF-induced monocyte adhesion and transmigration in mice. 29 This reveals the importance of CXCR2 in the myocardial recruitment of inflammatory monocytes.
Surprisingly, infiltration of the infarcted myocardial tissue with neutrophils was unaffected by MIF blockade or Cxcr2 deficiency. Neutrophils have been found to express CXCR2 Figure 4 . The analysis of angiogenesis in the infarcted area after anti-migrationinhibitory fact (MIF) antibody treatment after ischemia and reperfusion. Analysis of neoangiogenesis in the infarcted area (A) revealed no significant differences in the level of CD31-positive capillaries (red rings, right) between the groups 1 week after myocardial infarction (n=4-6; scale bars, 50 μm). Similarly, Langendorff measurements failed to reveal changes in coronary flow in any of the groups (B; n=4-6). BM indicates bone marrow; DAPI, 4',6-diamidino-2-phenylindole; and wt, wild type. but not CD74. 3 The moderate chemotactic activity toward MIF in neutrophils has been related to a lack of CD74 in these cells. 7 Because the function of MIF depends on the CXCR2/ CD74 complex, 7 the absence of CD74 might explain why neutrophil infiltration was unaltered in our myocardial I/R model. Furthermore, this is consistent with findings showing that early neutrophil infiltration after I/R injury was greatly diminished by Ccr1 deficiency and is hence dependent on the presence of the CCL5 receptor CCR1. 36 Unexpectedly, our evaluation of neoangiogenesis in the infarcted tissue 1 week after myocardial I/R injury failed to reveal changes in coronary flow or CD31-positive capillaries in any of the experimental groups. This is surprising, given that MIF and CXCR2 have been implicated in angiogenic responses 5 under hypoxic conditions by initiating tube formation and differentiation toward endothelial cell phenotypes or stimulating endothelial proliferation and capillary-like structure formation, respectively. 23, 24, 37 Our data support the notion that the MIF-CXCR2 pathway plays a minimal role in angiogenesis after MI and rather indicate the involvement of other factors, such as vascular endothelial growth factor or the CXCR4 ligand stromal cell-derived factor-1, acting through receptors other than CXCR2. 25 Another unexpected effect of MIF blockade was the CXCR2-independent reduction of collagen content in the infarcted area. Until recently, it was believed that reduced collagen content in the infarcted area might facilitate cardiac function. Our results rather indicate that increased collagen content in the infracted area can lead to a more stable myocardial scar and improved heart function.
30,38 Therefore, we assume that different collagen subtypes can be synthesized in response to MIF and, together with other factors, influence myocardial function. Accordingly, we have shown that MIF can favor the differentiation of smooth muscle actin-positive cells in vivo. 24 Furthermore, MIF in conjunction with CD74 can antagonize myocardial hypertrophy and fibrosis 39 and experimental liver fibrosis. 40 Thus, MIF may contribute to fibroblast differentiation toward smooth muscle actin-positive myofibroblasts, which is a crucial event in myocardial healing and scar formation. 30 Because the number of myofibroblasts did not differ in our groups, MIF seems to exert a direct effect on myofibroblast function and collagen synthesis. However, the mechanism underlying MIF-dependent fibrosis and scar formation after MI remains to be clarified in detail.
In conclusion, this study provides novel insights into the mechanisms of MIF and its functional receptor CXCR2 in myocardial regeneration and scar formation. Without affecting neutrophil infiltration or angiogenesis, MIF protects cardiac tissue via CXCR2. This benefit of MIF is counteracted by the CXCR2-dependent recruitment of monocytes associated with an impaired heart function. Our findings should be taken into account when developing tailored therapeutic strategies for improved remodeling and preservation of heart function after MI. The effect of anti-migrationinhibitory factor (MIF) antibody treatment on fibrosis after ischemia and reperfusion. Notably, collagen content (blue) was reduced in all 3 groups by treatment with anti-MIF antibody but not altered by Cxcr2 deficiency in bone marrow (BM) or resident cells (A; *P<0.05; n=4-6; scale bars, 50 μm), whereas the number of myofibroblasts (green) did not differ between the groups (B; n=4-6; scale bars, 50 μm). wt indicates wild type.
